Art. -Nr.: HY-14904

Umifenovir

12 Cited Publications

Kundenbewertung

Based on 12 publication(s) in Google Scholar

Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells. Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro. Umifenovir shows anti-inflammatory activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.04%
CAS. Nr.: 131707-25-0
Formel: C₂₂H₂₅BrN₂O₃S
Molecular Weight:477.41

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Umifenovir Chemical Structure

CAS. Nr.: 131707-25-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (12)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells^[1]^[2]. Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro^[2]. Umifenovir shows anti-inflammatory activity^[3].

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	EC₅₀	>200 μM Compound: Arbidol	Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 D1122N expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.6 by giemsa staining bas Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 D1122N expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.6 by giemsa staining bas	[PMID: 31753804]
HeLa	EC₅₀	>200 μM Compound: Arbidol	Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 E572K mutant expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staini Inhibition of Influenza A virus H3N2 A/X-31 hemagglutinin 3 E572K mutant expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staini	[PMID: 31753804]
HeLa	EC₅₀	40 μM Compound: Arbidol	Inhibition of influenza H3N2 A/X-31 hemagglutinin 3 expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staining based microscopic Inhibition of influenza H3N2 A/X-31 hemagglutinin 3 expressed in HeLa cells assessed as polykaryon formation preincubated for 15 mins and further incubated for 15 mins with acidic buffer containing compounds at pH 5.2 by giemsa staining based microscopic	[PMID: 31753804]
Huh-7	IC₅₀	1 μM Compound: Arbidol	Cytotoxicity against human Huh7.5 cells by celltiter-blue viability assay Cytotoxicity against human Huh7.5 cells by celltiter-blue viability assay	[PMID: 20638289]
MDCK	CC₅₀	46.44 μM Compound: arbidol	Cytotoxicity against dog MDCK cells incubated for 48 hrs by MTT assay Cytotoxicity against dog MDCK cells incubated for 48 hrs by MTT assay	[PMID: 33631936]
MDCK	IC₅₀	32.5 μM Compound: Arbidol	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay	[PMID: 32520560]
MRC5	CC₅₀	376 μM Compound: 2	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by neutral red staining-based microscopic analysis Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by neutral red staining-based microscopic analysis	[PMID: 28689975]
Vero	CC₅₀	161 μM Compound: Arbidol	Cytotoxicity against African green monkey Vero cells assessed as reduction in metabolic activity by MTS/PMS based microscopic analysis Cytotoxicity against African green monkey Vero cells assessed as reduction in metabolic activity by MTS/PMS based microscopic analysis	[PMID: 27856239]
Vero	CC₅₀	31.79 μM Compound: 16	Cytotoxicity against african green monkey Vero cells incubated for 3 days Cytotoxicity against african green monkey Vero cells incubated for 3 days	[PMID: 32539378]
Vero	CC₅₀	679.9 μM Compound: 2	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 18 hrs by neutral red staining-based microscopic analysis Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 18 hrs by neutral red staining-based microscopic analysis	[PMID: 28689975]
Vero	EC₅₀	35 μM Compound: Arbidol	Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect measured 5 days post infection by MTS/PMS based microscopic analysis Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect measured 5 days post infection by MTS/PMS based microscopic analysis	[PMID: 27856239]
Vero 76	IC₅₀	<20.9 μM Compound: Arbidol	Antiviral activity against CHIKV infected in Vero 76 cells assessed as reduction in cytopathic effect Antiviral activity against CHIKV infected in Vero 76 cells assessed as reduction in cytopathic effect	[PMID: 38394369]
Vero C1008	CC₅₀	>40 μM Compound: Arbidol	Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm) Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm)	10.1101/2020.04.03.023846
Vero C1008	CC₅₀	31.79 μM Compound: Arbidol	Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition by CCK8 assay	[PMID: 32771797]
Vero C1008	EC₅₀	10.7 μM Compound: Arbidol	Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days	10.1101/2020.04.03.023846

In Vitro

Umifenovir exhibits a wide range and potent antiviral activity against a number of viruses including influenza viruses A, B and C, respiratory syncytial virus, SARS-CoV, adenovirus, parainfluenza type 5, poliovirus 1, rhinovirus 14, coxsackievirus B5, hantaan virus, Chikungunya virus, HBV and HCV^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Umifenovir (25 and 45 mg/ml; p.o.) shows a survival benefit to mice suffering from influenza infection^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c mice (6–8 weeks old), mice were intranasally (i.n.) inoculated with 2 times the 50% mouse lethal dose (MLD₅₀) of A/ Guangdong/GIRD07/09 (H1N1) (10^4.5TCID₅₀/mL) in a volume of 20mL^[3].
Dosage:

1.25 mg/mL (25 mg/kg/day) and 2.25 mg/mL (45 mg/kg/day) in a total volume of 500mL at one day pre-infection and 3 days post-infection (dpi)
Administration:

Oral administration
Result:

Increased the survival rate, inhibited the decrease of body weight at 45 mg/mL and inhibited the increase of mice lung index at 25 mg/mL and 45 mg/mL comparing to virus group.

Chemical Information

CAS. Nr. 131707-25-0
Appearance Solid
Molecular Weight 477.41
Formel C₂₂H₂₅BrN₂O₃S
Color Off-white to light yellow
SMILES

O=C(C1=C(CSC2=CC=CC=C2)N(C)C3=C1C(CN(C)C)=C(O)C(Br)=C3)OCC
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (12)

All

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. [Abstract]

2021 Apr 24;6(1):165. PMID: 33895786
Nucleic Acids Res

COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]

2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390
Adv Sci (Weinh)

Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1. [Abstract]

2025 Oct 6:e10597. PMID: 41053536
mBio

Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model. [Abstract]

2021 Feb 22;13(1):e0304421. PMID: 35100870
J Enzyme Inhib Med Chem

Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity. [Abstract]

2025 Dec;40(1):2501743. PMID: 40371698
ACS Omega

Infectious cDNA Clone of Chikungunya Virus 181/25 for Antiviral Assay Development. [Abstract]

2025 Dec 8;10(50):62145-62156. PMID: 41476561
Viruses

3-Indoleacetonitrile Is Highly Effective in Treating Influenza A Virus Infection In Vitro and In Vivo. [Abstract]

2021 Jul 23;13(8):1433. PMID: 34452298
Viruses

Generation of a Reassortant Influenza A Subtype H3N2 Virus Expressing Gaussia Luciferase. [Abstract]

2019 Jul 20;11(7):665. PMID: 31330768
Brain Res

Cajanine alleviates anxiety and fear extinction deficits in female mice exposed to single prolonged stress via the ERβ/NF-κB pathway. [Abstract]

2026 Aug 15:1885:150331. PMID: 42009177
SSRN

2024 Jan 26.
Universidade de São Paulo

2020 Sep.
bioRxiv

2020 Mar.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (104.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0946 mL

10.4732 mL

20.9464 mL

5 mM

0.4189 mL

2.0946 mL

4.1893 mL

10 mM

0.2095 mL

1.0473 mL

2.0946 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Julie Blaising, et al. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014 Jul;107:84-94. doi: 10.1016/j.antiviral.2014.04.006. Epub 2014 Apr 24. [Content Brief]

[2]. Irina Leneva, et al. Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus. Viruses. 2021 Aug 23;13(8):1665. [Content Brief]

[3]. Yutao Wang, et al. Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret). Biomed Pharmacother. 2017 Jul;91:393-401. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0946 mL	10.4732 mL	20.9464 mL	52.3659 mL
	5 mM	0.4189 mL	2.0946 mL	4.1893 mL	10.4732 mL
	10 mM	0.2095 mL	1.0473 mL	2.0946 mL	5.2366 mL
	15 mM	0.1396 mL	0.6982 mL	1.3964 mL	3.4911 mL
	20 mM	0.1047 mL	0.5237 mL	1.0473 mL	2.6183 mL
	25 mM	0.0838 mL	0.4189 mL	0.8379 mL	2.0946 mL
	30 mM	0.0698 mL	0.3491 mL	0.6982 mL	1.7455 mL
	40 mM	0.0524 mL	0.2618 mL	0.5237 mL	1.3091 mL
	50 mM	0.0419 mL	0.2095 mL	0.4189 mL	1.0473 mL
	60 mM	0.0349 mL	0.1746 mL	0.3491 mL	0.8728 mL
	80 mM	0.0262 mL	0.1309 mL	0.2618 mL	0.6546 mL
	100 mM	0.0209 mL	0.1047 mL	0.2095 mL	0.5237 mL

Keywords

Umifenovir

12 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Umifenovir

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Off-patent Drug Library

Multi-Target Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Umifenovir

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Umifenovir

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Off-patent Drug Library

Multi-Target Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Umifenovir

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Umifenovir Related Classifications

HY-14904 Related Classifications